The role of lysosomes in limiting drug toxicity in mice[S]

Journal of Pharmacology and Experimental Therapeutics

Volumn 333, Issue 1, 2010, Pages 120-128

  Ndolo, Rosemary A ^a   Forrest, M Laird ^a   Krise, Jeffrey P ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

17 DEMETHOXY 17 (2 DIMETHYLAMINOETHYLAMINO)GELDANAMYCIN; ANTINEOPLASTIC AGENT; ARGINASE; CHLOROQUINE; CREATININE; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; PROTEIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PH; CELL PROTECTION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG SELECTIVITY; ENZYME BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIVER TOXICITY; LYSOSOME; MALE; MORBIDITY; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTINEOPLASTIC AGENTS; ARGINASE; BENZOQUINONES; CHLOROQUINE; CREATININE; HSP90 HEAT-SHOCK PROTEINS; HYDROGEN-ION CONCENTRATION; KIDNEY FUNCTION TESTS; LACTAMS, MACROCYCLIC; LIVER; LIVER FUNCTION TESTS; LYSOSOMES; MALE; MICE; MICE, INBRED C57BL; TISSUE DISTRIBUTION;

EID: 77949697283     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.160226     Document Type: Article

References (30)

1. Altan N, Chen Y, Schindler M, and Simon SM (1998) Defective acidification in human breast tumor cells and implications for chemotherapy. J Exp Med 187: 1583-1598.
2. Bach G, Chen CS, and Pagano RE (1999) Elevated lysosomal pH in Mucolipidosis type IV cells. Clin Chim Acta 280:173-179.
3. Belhoussine R, Morjani H, Sharonov S, Ploton D, and Manfait M (1999) Characterization of intracellular pH gradients in human multidrug-resistant tumor cells by means of scanning microspectrofluorometry and dual-emission-ratio probes. Int J Cancer 81:81-89.
4. de Duve C, de Barsy T, Poole B, Trouet A, Tulkens P, and Van Hoof F (1974) Commentary. Lysosomotropic agents. Biochem Pharmacol 23:2495-2531.
5. Dutcher JP, Novik Y, O'Boyle K, Marcoullis G, Secco C, and Wiernik PH (2000a) 20th-century advances in drug therapy in oncology-Part I. J Clin Pharmacol 40:1007-1024.
6. Dutcher JP, Novik Y, O'Boyle K, Marcoullis G, Secco C, and Wiernik PH (2000b) 20th-century advances in drug therapy in oncology-Part II. J Clin Pharmacol 40:1079-1092.
7. Duvvuri M, Konkar S, Hong KH, Blagg BS, and Krise JP (2006) A new approach for enhancing differential selectivity of drugs to cancer cells. ACS Chem Biol 1:309-315.
8. Falanga PB, Franco da Silveira JF, and Pereira da Silva L (1984) Protective immune response to Plasmodium chabaudi, developed by mice after drug controlled infection or vaccination with parasite extracts: analysis of stage specific antigens from the asexual blood cycle. Parasite Immunol 6:529-543.
9. Gerweck LE, Vijayappa S, and Kozin S (2006) Tumor pH controls the in vivo efficacy of weak acid and base chemotherapeutics. Mol Cancer Ther 5:1275-1279.
10. Glaze ER, Lambert AL, Smith AC, Page JG, Johnson WD, McCormick DL, Brown AP, Levine BS, Covey JM, Egorin MJ, et al. (2005) Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance. Cancer Chemother Pharmacol 56:637-647.
11. Gong Y, Duvvuri M, and Krise JP (2003) Separate roles for the Golgi apparatus and lysosomes in the sequestration of drugs in the multi-drug resistant human leukemic cell line HL-60. J Biol Chem 278:50234-50239.
12. Houshmand P and Zlotnik A (2003) Targeting tumor cells. Curr Opin Cell Biol 15:640-644. Imai K and Takaoka A (2006) Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6:714-727.
13. Jiang LW, Maher VM, McCormick JJ, and Schindler M (1990) Alkalinization of the lysosomes is correlated with ras transformation of murine and human fibroblasts. J Biol Chem 265:4775-4777.
14. Kokkonen N, Rivinoja A, Kauppila A, Suokas M, Kellokumpu I, and Kellokumpu S (2004) Defective acidification of intracellular organelles results in aberrant secretion of cathepsin D in cancer cells. J Biol Chem 279:39982-39988.
15. Kroemer G and Pouyssegur J (2008) Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13:472-482.
16. Lees DN and Stephen J (1985) Ectromelia virus-induced changes in primary cultures of mouse hepatocytes. J Gen Virol 66:2171-2181.
17. Mahoney BP, Raghunand N, Baggett B, and Gillies RJ (2003) Tumor acidity, ion trapping and chemotherapeutics. I. Acid pH affects the distribution of chemotherapeutic agents in vitro. Biochem Pharmacol 66:1207-1218.
18. Mehvar R, Robinson MA, and Reynolds JM (1994) Molecular weight dependent tissue accumulation of dextrans: in vivo studies in rats. J Pharm Sci 83:1495-1499.
19. Ng TC, Majors AW, Vijayakumar S, Baldwin NJ, Thomas FJ, Koumoundouros I, Taylor ME, Grundfest SF, Meaney TF, and Tubbs RR (1989) Human neoplasm pH and response to radiation therapy: P-31 MR spectroscopy studies in situ. Radiology 170:875-878.
20. Nilsson C, Kågedal K, Johansson U, and Öllinger K (2003) Analysis of cytosolic and lysosomal pH in apoptotic cells by flow cytometry. Meth Cell Sci 25:185-194.
21. Ohkuma S and Poole B (1978) Fluorescence probe measurement of the intralysosomal pH in living cells and the perturbation of pH by various agents. Proc Natl Acad Sci U S A 75:3327-3331.
22. Ozer J, Ratner M, Shaw M, Bailey W, and Schomaker S (2008) The current state of serum biomarkers of hepatotoxicity. Toxicology 245:194-205.
23. Poole B and Ohkuma S (1981) Effect of weak bases on the intralysosomal pH in mouse peritoneal macrophages. J Cell Biol 90:665-669.
24. Raghunand N, Mahoney BP, and Gillies RJ (2003) Tumor acidity, ion trapping and chemotherapeutics. II. pH-dependent partition coefficients predict importance of ion trapping on pharmacokinetics of weakly basic chemotherapeutic agents. Biochem Pharmacol 66:1219-1229.
25. Stella VJ and Himmelstein KJ (1980) Prodrugs and site-specific drug delivery. J Med Chem 23:1275-1282.
26. Supino R, Petrangolini G, Pratesi G, Tortoreto M, Favini E, Bo LD, Casalini P, Radaelli E, Croce AC, Bottiroli G, et al. (2008) Antimetastatic effect of a smallmolecule vacuolar H+-ATPase inhibitor in in vitro and in vivo preclinical studies. J Pharmacol Exp Ther 324:15-22.
27. Supko JG, Hickman RL, Grever MR, and Malspeis L (1995) Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 36:305-315.
28. Temesvari LA, Rodriguez-Paris JM, Bush JM, Zhang L, and Cardelli JA (1996) Involvement of the vacuolar proton-translocating ATPase in multiple steps of the endo-lysosomal system and in the contractile vacuole system of Dictyostelium discoideum. J Cell Sci 109:1479-1495.
29. Tian ZQ, Liu Y, Zhang D, Wang Z, Dong SD, Carreras CW, Zhou Y, Rastelli G, Santi DV, and Myles DC (2004) Synthesis and biological activities of novel 17-aminogeldanamycin derivatives. Bioorg Med Chem 12:5317-5329.
30. Young JC, Moarefi I, and Hartl FU (2001) Hsp90: a specialized but essential proteinfolding tool. J Cell Biol 154:267-273.